

GLAXOSMITHKLINE PLC  
Form 6-K  
October 12, 2016

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION  
Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of  
the Securities Exchange Act of 1934

For period ending 12 October 2016

GlaxoSmithKline plc  
(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS  
(Address of principal executive offices)

Indicate by check mark whether the registrant files or  
will file annual reports under cover Form 20-F or Form 40-F

Form 20-F  Form 40-F

--

Indicate by check mark whether the registrant by furnishing the  
information contained in this Form is also thereby furnishing the  
information to the Commission pursuant to Rule 12g3-2(b) under the  
Securities Exchange Act of 1934.

Yes No

GlaxoSmithKline plc (the 'Company')

Transaction notification

1. Details of PDMR/person closely associated with them ('PCA')
  - a) Name Sir Andrew Witty
  - b) Position/status Chief Executive Officer
  - c) Initial notification/ amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
  - a) Name GlaxoSmithKline plc
  - b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 

	Ordinary shares of 25 pence each ('Ordinary Shares')									
a) Description of the financial instrument	ISIN: GB0009252882									
b) Nature of the transaction	Acquisition of Ordinary Shares under the Company's ShareReward Plan.									
c) Price(s) and volume(s)	<table border="0" style="width: 100%;"> <tr> <td style="width: 15%;"></td> <td>Price(s)</td> <td>Volume(s)</td> </tr> <tr> <td></td> <td>£17.2781</td> <td>7 (partnership shares)</td> </tr> <tr> <td></td> <td>£17.2781</td> <td>7 (matching shares)</td> </tr> </table>		Price(s)	Volume(s)		£17.2781	7 (partnership shares)		£17.2781	7 (matching shares)
	Price(s)	Volume(s)								
	£17.2781	7 (partnership shares)								
	£17.2781	7 (matching shares)								
d) Aggregated information	14 Ordinary Shares									
Aggregated volume Price	£17.2781									
e) Date of the transaction	2016-10-11									
f) Place of the transaction	London Stock Exchange (XLON)									

1. Details of PDMR/person closely associated with them ('PCA')
  - a) Name Mr R G Connor
  - b) Position/status President, Global Manufacturing & Supply
  - c) Initial notification/ amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
  - a) Name GlaxoSmithKline plc
  - b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

a) Description of the financial instrument	Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
b) Nature of the transaction	Acquisition of Ordinary Shares under the Company's ShareReward Plan.
c) Price(s) and volume(s)	Price(s) Volume(s) £17.2781 7 (partnership shares) £17.2781 7 (matching shares)
d) Aggregated information	14 Ordinary Shares
Aggregated volume Price	£17.2781
e) Date of the transaction	2016-10-11
f) Place of the transaction	London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')

a) Name	Mr S Dingemans
b) Position/status	Chief Financial Officer
c) Initial notification/ amendment	Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name	GlaxoSmithKline plc
b) LEI	5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a) Description of the financial instrument	Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
b) Nature of the transaction	Acquisition of Ordinary Shares under the Company's ShareReward Plan.
c) Price(s) and volume(s)	Price(s) Volume(s) £17.2781 7 (partnership shares) £17.2781 7 (matching shares)
d) Aggregated information	14 Ordinary Shares
Aggregated volume Price	£17.2781

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

e) Date of the transaction 2016-10-11  
 f) Place of the transaction London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')  
 a) Name Mr N Hirons  
 b) Position/status SVP, Global Ethics & Compliance  
 c) Initial notification/  
 amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction  
 platform, auctioneer or auction monitor  
 a) Name GlaxoSmithKline plc  
 b) LEI 5493000HZTVUYLO1D793  
 3. Details of the transaction(s): section to be repeated for (i) each type of  
 instrument; (ii) each type of transaction; (iii) each date; and (iv) each place  
 where transaction(s) has been conducted

Ordinary shares of 25 pence each  
 ('Ordinary Shares')  
 a) Description of the financial instrument ISIN: GB0009252882

b) Nature of the transaction Acquisition of Ordinary Shares  
 under the Company's  
 ShareReward Plan.

c) Price(s) and Volume(s)  
 volume(s) £17.2781 8 (partnership shares)  
 £17.2781 8 (matching shares)

d) Aggregated information 16 Ordinary Shares  
 Aggregated volume Price £17.2781

e) Date of the transaction 2016-10-11  
 f) Place of the transaction London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')  
 a) Name Mr S A Hussain  
 b) Position/status President, Global Pharmaceuticals  
 c) Initial notification/  
 amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction  
 platform, auctioneer or auction monitor  
 a) Name GlaxoSmithKline plc  
 b) LEI 5493000HZTVUYLO1D793

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)	Description of the financial instrument	Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882						
b)	Nature of the transaction	Acquisition of Ordinary Shares under the Company's ShareReward Plan.						
c)	Price(s) and volume(s)	<table border="0"> <tr> <td>Price(s)</td> <td>Volume(s)</td> </tr> <tr> <td>£17.2781</td> <td>7 (partnership shares)</td> </tr> <tr> <td>£17.2781</td> <td>7 (matching shares)</td> </tr> </table>	Price(s)	Volume(s)	£17.2781	7 (partnership shares)	£17.2781	7 (matching shares)
Price(s)	Volume(s)							
£17.2781	7 (partnership shares)							
£17.2781	7 (matching shares)							
d)	Aggregated information Aggregated volume Price	14 Ordinary Shares £17.2781						
e)	Date of the transaction	2016-10-11						
f)	Place of the transaction	London Stock Exchange (XLON)						

1. Details of PDMR/person closely associated with them ('PCA')

a)	Name	Mr D S Redfern
b)	Position/status	Chief Strategy Officer
c)	Initial notification/ amendment	Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)	Name	GlaxoSmithKline plc
b)	LEI	5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)	Description of the financial instrument	Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882				
b)	Nature of the transaction	Acquisition of Ordinary Shares under the Company's ShareReward Plan.				
c)	Price(s) and volume(s)	<table border="0"> <tr> <td>Price(s)</td> <td>Volume(s)</td> </tr> <tr> <td>£17.2781</td> <td>8 (partnership shares)</td> </tr> </table>	Price(s)	Volume(s)	£17.2781	8 (partnership shares)
Price(s)	Volume(s)					
£17.2781	8 (partnership shares)					

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

£17.2781 8 (matching shares)

Aggregated information  
d) 16 Ordinary Shares  
Aggregated volume Price £17.2781  
e) Date of the transaction 2016-10-11  
f) Place of the transaction London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')  
a) Name Ms C Thomas  
b) Position/status SVP, Human Resources  
c) Initial notification/ amendment Initial notification  
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor  
a) Name GlaxoSmithKline plc  
b) LEI 5493000HZTVUYLO1D793  
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')  
ISIN: GB0009252882

b) Nature of the transaction Acquisition of Ordinary Shares under the Company's ShareReward Plan.

c) Price(s) and volume(s)  
Price(s) Volume(s)  
£17.2781 8 (partnership shares)  
£17.2781 8 (matching shares)

Aggregated information  
d) 16 Ordinary Shares  
Aggregated volume Price £17.2781  
e) Date of the transaction 2016-10-11  
f) Place of the transaction London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')  
a) Name Mr P C Thomson  
b) Position/status SVP, Communications & Government Affairs  
c) Initial notification/ Initial notification

amendment

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
  - a) Name GlaxoSmithKline plc
  - b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
  - a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')  
ISIN: GB0009252882
  - b) Nature of the transaction Acquisition of Ordinary Shares under the Company's ShareReward Plan.
  - c) Price(s) and volume(s)
 

Price(s)	Volume(s)
£17.2781	7 (partnership shares)
£17.2781	7 (matching shares)
  - d) Aggregated information
 

Aggregated volume	14 Ordinary Shares
Price	£17.2781
  - e) Date of the transaction 2016-10-11
  - f) Place of the transaction London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')
  - a) Name Dr P J T Vallance
  - b) Position/status President, Pharmaceuticals R&D
  - c) Initial notification/ amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
  - a) Name GlaxoSmithKline plc
  - b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
  - a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')  
ISIN: GB0009252882
  - b) Nature of the transaction Acquisition of Ordinary Shares under the Company's ShareReward Plan.

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

c) Price(s) and volume(s)	Price(s) Volume(s) £17.2781 7 (partnership shares) £17.2781 7 (matching shares)
d) Aggregated information Aggregated volume Price	14 Ordinary Shares £17.2781
e) Date of the transaction	2016-10-11
f) Place of the transaction	London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')
  - a) Name Ms E Walmsley
  - b) Position/status CEO Designate
  - c) Initial notification/ amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
  - a) Name GlaxoSmithKline plc
  - b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
  - a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')  
ISIN: GB0009252882
  - b) Nature of the transaction Acquisition of Ordinary Shares under the Company's ShareReward Plan.

c) Price(s) and volume(s)	Price(s) Volume(s) £17.2781 8 (partnership shares) £17.2781 8 (matching shares)
d) Aggregated information Aggregated volume Price	16 Ordinary Shares £17.2781
e) Date of the transaction	2016-10-11
f) Place of the transaction	London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')
  - a) Name Mrs V A Whyte



Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

- |   |   |
|---|---|
| b) Position/status  | Company Secretary   |
| c) Initial notification/<br>amendment   | Initial notification  |
| 2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor  |   |
| a) Name   | GlaxoSmithKline plc   |
| b) LEI  | 5493000HZTVUYLO1D793  |
| 3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |   |
| a) Description of the financial instrument  | Ordinary shares of 25 pence each ('Ordinary Shares')<br>ISIN: GB0009252882            |
| b) Nature of the transaction  | Acquisition of Ordinary Shares under the Company's ShareReward Plan.                  |
| c) Price(s) and volume(s)   | Price(s) Volume(s)<br>£17.2781 7 (partnership shares)<br>£17.2781 7 (matching shares) |
| d) Aggregated information<br>Aggregated volume Price  | 14 Ordinary Shares<br>£17.2781  |
| e) Date of the transaction  | 2016-10-11  |
| f) Place of the transaction   | London Stock Exchange (XLON)  |

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc  
(Registrant)  
Date: October 12, 2016

By: VICTORIA WHYTE  
-----

Victoria Whyte

Authorised Signatory for and on  
behalf of GlaxoSmithKline plc